NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs . NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor . NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect.
Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > DNA-PK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.